Last updated Nov 4, 2026
An infant with macrocephaly and hypotonia develops progressive spasticity, visual impairment, and seizures. MRI shows diffuse white matter involvement. N-acetylaspartic acid is elevated in urine.
AR; ASPA (aspartoacylase, which breaks down N-acetylaspartic acid in the brain). Biallelic loss-of-function variants; residual activity separates typical from atypical disease.
- Common in Ashkenazi Jewish population
Aspartoacylase converts N-acetylaspartic acid (NAA) to aspartate and acetate. NAA is abundant in the brain, where this hydrolysis is thought to help maintain white matter. The enzyme is expressed throughout the body, but its loss in the central nervous system produces a specific buildup of NAA in the brain, which causes demyelination and the other signs of the disease: the leukodystrophy, macrocephaly, and hypotonia that turns to spasticity.
Residual activity tracks severity:
- Typical Canavan disease (85% to 90%): the Ashkenazi Jewish founder variants p.Tyr231Ter and p.Glu285Ala abolish activity, homozygous or in combination.
- Atypical Canavan disease (10% to 15%): missense variants that keep more activity (p.Arg71His, p.Asp204His, p.Pro257Arg, p.Tyr288Cys) give a milder, later course, even when paired with a null allele. Urine NAA is only about 10-fold raised.
- p.Ala305Glu, common in Europeans without Ashkenazi ancestry, leaves very low activity and appears in both forms.
An intronic retrotransposon insertion of about 2.6 kb creates an aberrant splice site; exome and short-read genome sequencing miss it, so long-read testing is considered when no variant is found. It may be the most common ASPA variant across ancestries.
Part of creatine and N-acetylaspartate metabolism.
N-acetylaspartic acid (NAA) breakdown; NAA is abundant in the brain.
acetyl-CoA + aspartate → N-acetylaspartic acid (NAA) → aspartoacylase (the block) → aspartate + acetate
- Accumulates: N-acetylaspartic acid, measured in urine organic acids (also high in blood and CSF) and as a raised NAA peak on MR spectroscopy.
- Missing: the NAA hydrolysis that is thought to help maintain brain white matter.
- Workbook: 4.M. Canavan disease
- Leukodystrophy (spongiform white matter degeneration)
- Macrocephaly (progressive)
- Hypotonia → spasticity
- Severe developmental regression
- Visual impairment, optic atrophy
- Elevated N-acetylaspartic acid (NAA) in urine, blood, CSF
- MRI: diffuse white matter changes, subcortical U-fiber involvement
Carrier Screening: Included in Ashkenazi Jewish panel
- Not on RUSP; suspected clinically (macrocephaly, leukodystrophy on MRI)
- Markedly elevated N-acetylaspartic acid (NAA) on urine organic acids; elevated NAA peak on MR spectroscopy
- Confirmation: deficient aspartoacylase activity or biallelic ASPA variants
- Supportive only: no disease-modifying therapy
- Seizure control, feeding/nutrition support, management of spasticity, physical therapy
- ASPA gene therapy under investigation
CaNAAvan has elevated NAA: Canavan disease is diagnosed by elevated N-acetylaspartic acid (NAA) on urine organic acids and MR spectroscopy.